Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort

Abstract excerpt

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by α-galactosidase A (α-Gal A) deficiency. The progressive accumulation of globotriaosylceramide results in life-threatening complications, including renal, cardiac, and cerebrovascular diseases. The pharmacological chaperone migalastat was recently approved as an alternative to enzyme replacement therapy in patients with amenable mutations....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomedical Research and Pathophysiology
• Share to Lysosomal Storage Disorders Research
• Share to Trypanosoma species research and implications